NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will present and host one-on-one investor meetings at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will prese ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange. During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic ini ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, announced today the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3™, which received FDA clearance last month. Butterfly iQ3 is powered by the Company’s most advanced semiconductor chip with a data tr ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, provided a business update today at the 42nd Annual J.P. Morgan Healthcare Conference. A webcast replay of the conference presentation can be viewed here, and will be available until February 10th, 2024. The presentation slide deck with animated videos can be accessed here ...

8 Changes in Internal Control over Financial Reporting We are currently and may in the future be subject to legal proceedings, claims, and regulatory actions arising in the ordinary course of business. The outcome of any such matters, regardless of the merits, is inherently uncertain. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds We did not repurchase any of our equity securities during the three months ended September 30, 2023. Item 5. Other Information See Exhibit Index. EXHIBIT INDE ...

Butterfly Network, Inc. (NYSE:BFLY) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Heather Getz - Chief Financial and Operations Officer Joseph DeVivo - Chairman & Chief Executive Officer Conference Call Participants Joshua Jennings - TD Cowen Suraj Kalia - Oppenheimer Operator Hello. Thank you for attending the Butterfly Network Q3 2023 Earnings Call. My name is Victoria, and I'll be your moderator today. All lines will be muted during the presentation portion of the call ...

Butterfly Network, Inc. (NYSE:BFLY) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Heather Getz - Executive Vice President & Chief Financial Officer Joseph DeVivo - Chairman & Chief Executive Officer Conference Call Participants Suraj Kalia - Oppenheimer & Co. Neil Chatterji - B. Riley Securities Joshua Jennings - Cowen Danielle Antalffy - UBS Operator Ladies and gentlemen, hello, and welcome to the Butterfly Network Q2 2023 Earnings Call. My name is Maxine, and I'll be coor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Butterfly Network, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - Revenue for Q1 2023 was $15.5 million, essentially flat compared to the prior year period [48] - Gross profit was $9.1 million in Q1 2023, compared to $8.3 million in the prior year period, with a gross profit margin of 59% [49] - Adjusted EBITDA loss was $22.3 million, an improvement from a loss of $39.7 million for the same period in 2022 [49] Business Line Data and Key Metrics Changes - Product revenue was $8.8 million, a decrease of 20% versus Q1 2022, driven by lower volume across all segments except global health [22] - Software and services revenue was $6.6 million, growing by 45% over the prior year period, with software and services making up 43% of total revenue [22] Market Data and Key Metrics Changes - U.S. direct business saw a 15% increase driven by higher subscription revenue [48] - There was softness in other channels, including e-commerce, international distribution, and veterinary [48] Company Strategy and Development Direction - The company aims to leverage its Ultrasound-on-Chip technology to enhance accessibility and ease of use for medical professionals [14] - A focus on AI applications is central to the company's strategy, with plans to monetize AI algorithms across its large installed base [41] - The company is committed to evaluating its strategy under new leadership and will provide updated guidance in the next earnings call [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged disruptions in Q1 due to leadership changes and a reduction in force, but expects sequential revenue growth in Q2 [23] - The company has a solid cash position, with cash and cash equivalents of $198 million as of March 31, 2023 [3] - Management expressed optimism about the potential for growth in the home care market and the importance of software monetization [94] Other Important Information - The company has signed significant deals with large medical institutions to deploy its solutions, enhancing medical education and training [18] - The recent FDA approval of new tools is expected to drive further adoption and market penetration [19] Q&A Session Summary Question: What is the outlook for the U.S. commercial team? - The U.S. direct channel is expected to continue showing strength, with recent deals signed with major medical schools [87] Question: How is the company addressing the home care opportunity? - The home and offsite market is seen as a massive opportunity, with ongoing efforts to define regulatory pathways with the FDA [94] Question: What is the strategy for software monetization? - The company plans to create different levels of software bundles to monetize new capabilities as they are developed [53]

Table of Contents FORM 10-Q Butterfly Network, Inc. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has ...